Egis feels confident about the future through innovation and commitment to the continuous development
Egis Pharmaceuticals PLC, headquartered in Budapest, Hungary, is known on the international market primarily for the unique pharmaceutical technologies of high-quality generics providing significant benefits in prevention and treatment of many common diseases. The Russian market has been strategically important for the company over the several decades. On March 1, 2016, Tamas Endrenyi, having 15 years international experience of leadership in pharmaceutical industry, took over as the Chief Executive Officer of the Russian representative office of Egis. Commenting on his appointment, Tamas Endrenyi said: «The pharmaceutical environment is changing rapidly and Egis must be active on this market. Such dynamics requires us to constantly develop new technologies, operational management decisions. The company's position will be further strengthened in Russia due to our competitive advantages, such as long-term industry competences and dedication to quality, considerable production capacity and focus on technological innovations, our products credibility among doctors and patients which are widely used by them for more than 65 years in Russia».